Form 4: Aquestive Therapeutics: Officer Tax Withholding on RSUs

Aquestive Therapeutics reports Sherry Korczynski's transaction involving shares withheld for tax obligations related to Restricted Stock Units.

Summary

• Sherry Korczynski, Chief Commercial Officer at Aquestive Therapeutics, Inc., had 2,714 shares of common stock withheld by the company.
• These shares were used to satisfy her tax withholding obligations upon the vesting of previously granted Restricted Stock Units (RSUs).
• The transaction occurred on June 8, 2026, and the shares were acquired directly by the issuer.
• Following this transaction, Korczynski beneficially owns 238,403 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine administrative transaction related to executive compensation and tax obligations, rather than a significant strategic event.

Positives

• Successful settlement of tax obligations related to RSU vesting, indicating proper corporate procedures.
• Continued direct beneficial ownership of a significant number of shares (238,403) by a key executive, suggesting alignment with shareholder interests.

Negatives

• Withholding of shares for tax purposes reduces the number of shares directly held by the reporting person, though this is a standard practice.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, such as the tax withholding related to equity awards, which is a common practice across the pharmaceutical and biotechnology sectors.

Corporate Governance

Related Party Transactions

• The transaction involves shares withheld by Aquestive Therapeutics, Inc. to satisfy the tax obligations of its Chief Commercial Officer, Sherry Korczynski, in connection with the vesting of her RSUs. This is a standard related-party transaction concerning executive compensation.

Stakeholder Impact

• Shareholders: The withholding of shares for tax purposes is a standard practice and does not inherently impact shareholder value, though it reduces the direct shareholding of the executive by the amount withheld.
• Employees: This filing is specific to executive compensation and tax handling, with no direct impact on general employees.
• Management: Confirms the standard procedures for managing equity-based compensation and associated tax liabilities.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Form 4, SEC Filing, Restricted Stock Units, RSUs, Tax Withholding, Beneficial Ownership, Sherry Korczynski, Chief Commercial Officer